About Aperture Venture Partners
Aperture Venture Partners is a venture capital firm founded in 2002. It is primarily based out of New York City, United States. As of Mar 2025, Aperture Venture Partners has invested in 45 companies. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series E round of Shoulder Innovations Overall, Aperture Venture Partners portfolio has seen 7 IPOs and 20 acquisitions including key companies like Inspire Medical, Tarsus and Nalu Medical. A lot of funds co-invest with Aperture Venture Partners, with names like Western Technology Investment sharing a substantial percentage of its portfolio. Aperture Venture Partners has team of 4 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series C, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Aperture Venture Partners' List of Top Investments
Aperture Venture Partners has a portfolio of 45 companies. Their most notable investments are in Ceptaris Therapeutics and Ceptaris Therapeutics.Their portfolio spans across United States, Canada and Israel. They have invested in Life Sciences, HealthTech, Enterprise Applications and 5 other sectors, across stages such as Series C, Series B and 4 more. Here is the list of top investments by Aperture Venture Partners:Developer of neurostimulation device to treat sleep apnea. The company uses neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient’s unique breathing patterns to treat Obstructive Sleep Apnea.
Key facts about Inspire Medical
- Founded Year: 2007
- Location: Maple Grove (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $109M
- Employee Count: 1,319 as on Aug 31, 2026
- Investors: Medtronic, Kleiner Perkins and 8 Others
- Latest Funding Round: Series F, Nov 07, 2016, $*****
- Highlight: Public
2. Tarsus
Tarsus is developing a drug to treat blepharitis. The lead compound is a topical ophthalmic drug called TP-03 developed for the treatment of Demodex blepharitis will undergo Phase 2b/3 trials. The company's product pipeline also includes the development of drugs for other eye problems.
Key facts about Tarsus
- Founded Year: 2017
- Location: Irvine (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $60M
- Employee Count: 436 as on Aug 31, 2026
- Investors: RTW Investments, Vivo Capital and 5 Others
- Latest Funding Round: Series B, Jan 08, 2020, $*****
- Highlight: Acquired
3. Nalu Medical
Developer of a neurostimulation system for managing intractable chronic pain. The company offers Nalu neurostimulation system which is a micro-implantable pulse generator is used for Spinal Cord Stimulation and Peripheral Nerve Stimulation. The device uses gentle electrical impulses to interrupt pain signals.
Key facts about Nalu Medical
- Founded Year: 2014
- Location: Carlsbad (United States)
- Stage: Acquired
- Total Funding till date: $231M
- Employee Count: 214 as on Aug 31, 2026
- Investors: Gilde Healthcare, Advent Life Sciences and 9 Others
- Latest Funding Round: Series E, Dec 21, 2023, $*****
- Highlight: Acquired
4. Endotronix
Provider of device for Measurement of Hemodynamic parameters for heart failure maangement. It develops miniaturized wireless and implantable pressure sensors to communicate pressures that accurately measure cardiac function and provide software and services to personalize the patient care experience. The solution aims to accurately capture pulmonary artery pressure data using a mobile device. The data will be securely transmitted from the remote location to the patient’s Clinical Care Team for review and analysis.
Key facts about Endotronix
- Founded Year: 2007
- Location: East Peoria (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $155M
- Employee Count: 101 as on Mar 31, 2026
- Investors: Life Sciences Partners, EQT and 14 Others
- Latest Funding Round: Series D, Oct 01, 2019, $*****
- Highlight: Acquired
Developer of therapies targeting neurological and neuropsychiatric diseases. The company's drug pipeline includes BHV-0223, a novel formulation of a glutamate-modulating agent, being developed under the FDA. It also provides a BHV-4157glutamate modulator for the treatment of spinocerebellar ataxia (SCA), SHV-5000i targeting NMDA receptor antagonism for post-traumatic stress disorder, and treatment-resistant depression.
Key facts about Biohaven Pharmaceutical
- Founded Year: 2014
- Location: New Haven (United States)
- Stage: Acquired
- Total Funding till date: $84.1M
- Employee Count: 397 as on Sep 30, 2026
- Investors: Venrock, Foresite Capital and 13 Others
- Latest Funding Round: Series C, Mar 07, 2017, $*****
- Highlight: Acquired
Aperture Venture Partners' Year-on-Year Investment Trends
Aperture Venture Partners has invested in 45 companies over the last 22 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 1 investment. Its most recent first time investment was in Miach Orthopaedics and most recent follow-on round was in Shoulder Innovations.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 1 | 1 |
2024 | 1 | 2 | 3 |
2023 | 1 | 3 | 4 |
2022 | 3 | 0 | 3 |
2021 | 1 | 1 | 2 |
2020 | 1 | 3 | 4 |
2019 | 4 | 1 | 5 |
2018 | 3 | 2 | 5 |
2017 | 3 | 2 | 5 |
Aperture Venture Partners' Investments by Stage
Aperture Venture Partners has made 12 investments in Series C stage with an average round size of $42.9M, 10 investments in Series B stage with an average round size of $36.7M and 7 investments in Series A stage with an average round size of $21.4M.Stage of entry | No. of Investments |
|---|---|
Series C | 12 |
Series B | 10 |
Series A | 7 |
Series D | 2 |
Series E | 2 |
Others | 1 |
Note: We have considered here, only first round of investments
Aperture Venture Partners' Investments by Sector
Aperture Venture Partners has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Internet of Things - Industry Applications and Consumer. Notably, it has invested in 39 Tech companies, 35 Enterprise (B2B) companies, 14 Tech hardware companies and at least 8 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 30 |
High Tech | 6 |
HealthTech | 5 |
Internet of Things - Industry Applications | 3 |
Consumer | 2 |
Others | 9 |
Note: We have considered here, only first round of investments
Aperture Venture Partners' Investments by Geography
Aperture Venture Partners has made most investments in United States (33), followed by Israel where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 33 |
Israel | 1 |
Note: We have considered here, only first round of investments
Aperture Venture Partners' recent investments
Aperture Venture Partners has not made any investment in 2026 so far.Here are the most recent investments by Aperture Venture Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 06, 2025 | United States | Series E | 3250 | [+4] | |
Sep 17, 2024 | United States | Series B | 9006 | [+5] | |
Aug 20, 2024 | United States | Series B | 5944 | [+5] | |
Apr 02, 2024 | United States | Series B | 8155 | [+7] | |
Dec 21, 2023 | United States | Series E | 9488 | [+8] |
IPOs and Publicly Listed companies in Aperture Venture Partners' Portfolio
7 of Aperture Venture Partners' portfolio companies have become public. Shoulder Innovations got listed on the New York Stock Exchange (NYSE), in Jul 2025 at marketcap of $299M and Trevi Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Aperture Venture Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 31, 2025 | Feb 22, 2023 | Series D | 7551 | |
May 07, 2019 | Sep 05, 2018 | Series C | 5762 | |
May 04, 2018 | May 15, 2014 | Series E | 3317 | |
Oct 13, 2017 | - | - | 8746 | |
May 04, 2017 | - | - | 9220 |
Acquired companies in Aperture Venture Partners' Portfolio
20 companies from Aperture Venture Partners' portfolio have been acquired. The most recent acquisition was Nalu Medical in Oct 2025 by Boston Scientific for $*****.Here are Aperture Venture Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 17, 2025 | Feb 17, 2022 | Series B | 3204 | |
Aug 20, 2024 | 2017 | Series C | 7450 | |
Jul 01, 2024 | Feb 26, 2018 | Series C | 4017 | |
Jul 07, 2022 | Jan 08, 2020 | Series B | 1044 | |
May 10, 2022 | Nov 10, 2016 | Series C | 7098 |
Team profile of Aperture Venture Partners
Aperture Venture Partners has a team of 4 members including 4 Partners located in United States. Aperture Venture Partners' team does not sit on the board of any company as of now.Here is a list of all team members in Aperture Venture Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Diego | - | ||
Partner | New York | - | ||
Partner | New York City | - | ||
Partner | New York City | - | - |
Co-investors of Aperture Venture Partners
Over the past 22 years, 261 investors have co-invested in Aperture Venture Partners's portfolio companies. This includes funds and angels.
- Invested before Aperture Venture Partners: Johnson & Johnson Innovation – JJDC, RiverVest Venture Partners and 84 others have invested in rounds before Aperture Venture Partners. There are 3 companies where Johnson & Johnson Innovation – JJDC has invested before Aperture Venture Partners and 3 companies where RiverVest Venture Partners has invested before Aperture Venture Partners.
- Top Co-investors of Aperture Venture Partners: 100 investors entered a company along with Aperture Venture Partners. These include investors like Western Technology Investment (4 companies).
- Invested after Aperture Venture Partners: A total of 75 investors have invested in Aperture Venture Partners's portfolio after their investments. Top Investors include Third Point (3 companies), Amzak Health (2 companies) and EQT (2 companies).
Recent News related to Aperture Venture Partners
•
Shoulder Innovations Announces Closing of $40 Million Series E Equity Financingintelligence360•Mar 14, 2025•Shoulder Innovations, Usventure, Sectoral, Arboretum Ventures and 3 others
•
Shoulder Innovations Closes $40M in Series E Equity FinancingFinSMEs•Mar 10, 2025•Shoulder Innovations, USVP, Gilde Healthcare, Gilmartin Capital and 3 others
•
ShiraTronics Raises $66M in Series B Funding for Chronic Migraine Treatment DevelopmentFemtech Insider•Oct 18, 2024•ShiraTronics, Norwest Venture Partners, Seroba Lifesciences, OSF Innovation and 4 others
•
ShiraTronics raises $66M to support implantable migraine therapyMassDevice•Oct 09, 2024•ShiraTronics, Norwest Venture Partners, OSF Innovation, Global BioAccess and 6 others
•
Xii medical raises $45 million in series b financing to advance best-in-class neuromodulation therapy for obstructive sleep apneaPR Newswire•Aug 21, 2024•XII Medical, Omega Funds, Intuitive, Cleveland Clinic and 4 others
•
Miach Orthopaedics Raises $20 Million in Series B ExtensionOrthoSpineNews•Apr 02, 2024•Miach Orthopaedics, MLSPA, SV Health Investors, Aperture Venture Partners and 6 others
•
Nalu Medical: $85 Million Raised To Develop Non-Pharmacologic Solutions For Chronic Neuropathic PainPulse 2.0•Mar 09, 2024•Nalu Medical, B Capital, Gilde Healthcare, MVM and 8 others
•
Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic PainWvnews•Jan 03, 2024•Nalu Medical, Novo Holdings, Gilde Healthcare, MVM and 7 others
•
Autism Provider Cortica Secures $75M Funding Round, Acquires 2 CompaniesBehavioral Health Business•Apr 17, 2023•Cortica, Deerfield, Optum Ventures, RA Capital Management and 10 others
•
Michigan medical startup raises $42M in Series D fundingpcdn.co•Mar 07, 2023•Shoulder Innovations, Gilde Healthcare, USVP, Lightstone Ventures and 3 others
